How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,389 results for

Potassium Replacement

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Renin-angiotensin II-aldosterone system blockers and time to renal replacement therapy in children with CKD. Full Text available with Trip Pro

Renin-angiotensin II-aldosterone system blockers and time to renal replacement therapy in children with CKD. Clinical care decisions to treat chronic kidney disease (CKD) in a growing child must often be made without the benefit of evidence from clinical trials. We used observational data from the Chronic Kidney Disease in Children cohort to estimate the effectiveness of renin-angiotensin II-aldosterone system blockade (RAAS) to delay renal replacement therapy (RRT) in children with CKD.A total (...) proteinuria, anemia, elevated blood pressure, acidosis, elevated phosphate and elevated potassium.There were 217 RRT events over a 4.1-year median follow-up. At baseline, 472 children (55 %) were prevalent RAAS users, who were more likely to be older, have a glomerular etiology, have higher urine protein, be anemic, have elevated serum phosphate and potassium, take more medications, but less likely to have elevated blood pressure, compared with non-users. RAAS use was found to reduce the risk of RRT by 21

2016 Pediatric Nephrology

102. A curious case of persistently relapsing hyperkalemia in an ESRD patient on maintenance hemodialysis following bioprosthetic aortic valve replacement – a potential case for the use of the new agent, patiromer, for hyperkalemia management Full Text available with Trip Pro

, and sometimes the adverse effects of medications such as RAAS blocking agents. Moreover, hyperkalemia following extended cardiac surgery can result from the use of high-potassium containing cardioplegic solutions used during cardiopulmonary bypass. Nevertheless, different from the foregoing, in the nephrology literature, there have been very rare reports of potentially life-threatening hyperkalemia following cardiac valve replacement procedure. We recently encountered an unusual case of persistent relapsing (...) A curious case of persistently relapsing hyperkalemia in an ESRD patient on maintenance hemodialysis following bioprosthetic aortic valve replacement – a potential case for the use of the new agent, patiromer, for hyperkalemia management Hyperkalemia is not uncommon in patients with end-stage renal disease (ESRD) on maintenance hemodialysis, often related to dietary indiscretion, following the prolonged inter-dialytic weekend interval in patients on thrice weekly hemodialysis treatments

2016 Journal of renal injury prevention

103. Furosemide Stress Test Guiding Initiation of Renal Replacement Therapy

Furosemide Stress Test Guiding Initiation of Renal Replacement Therapy Furosemide Stress Test Guiding Initiation of Renal Replacement Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Furosemide (...) Stress Test Guiding Initiation of Renal Replacement Therapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02730117 Recruitment Status : Completed First Posted : April 6, 2016 Last Update Posted : December 19, 2017 Sponsor: Chulalongkorn University Information provided by (Responsible Party

2016 Clinical Trials

104. Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)

Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02860130 Recruitment Status : Terminated (Study

2016 Clinical Trials

105. On Demand Versus Protocol-guided Renal Replacement Therapy for Management of Stage 3 Acute Kidney Injury in Patients With Cirrhosis

On Demand Versus Protocol-guided Renal Replacement Therapy for Management of Stage 3 Acute Kidney Injury in Patients With Cirrhosis On Demand Versus Protocol-guided Renal Replacement Therapy for Management of Stage 3 Acute Kidney Injury in Patients With Cirrhosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. On Demand Versus Protocol-guided Renal Replacement Therapy for Management of Stage 3 Acute Kidney Injury in Patients With Cirrhosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2016 Clinical Trials

106. Alkali replacement raises urinary citrate excretion in patients with topiramate‐induced hypocitraturia Full Text available with Trip Pro

Alkali replacement raises urinary citrate excretion in patients with topiramate‐induced hypocitraturia The aims of this study were to assess (1) the magnitude and temporality of decreased urinary citrate excretion in patients just starting topiramate and (2) the effect of alkali replacement on topiramate-induced hypocitraturia.Study 1 was a prospective, non-intervention study in which patients starting topiramate for headache remediation provided pre- and post-topiramate 24 h urine (...) hypocitraturia (citrate <320 mg day(-1) ). At 60 days, urine citrate was even lower than at baseline (P = 0.0032) and 86% of patients had developed hypocitraturia. After starting alkali, urine citrate increased in stone-forming patients on topiramate (198 ± 120 to 408 ± 274 mg day(-1) ; P = 0.042 for difference). 85% of patients were hypocitraturic on topiramate alone vs. 40% after adding alkali. The increase in urinary citrate was greater in patients provided ≥ 90 mEq potassium citrate.Our study

2015 British journal of clinical pharmacology

107. The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement

: tolvaptan safety and efficacy left heart valves replacement Additional relevant MeSH terms: Layout table for MeSH terms Heart Failure Tricuspid Valve Insufficiency Heart Diseases Cardiovascular Diseases Heart Valve Diseases Tolvaptan Torsemide Antidiuretic Hormone Receptor Antagonists Molecular Mechanisms of Pharmacological Action Natriuretic Agents Physiological Effects of Drugs Antihypertensive Agents Diuretics Sodium Potassium Chloride Symporter Inhibitors Membrane Transport Modulators (...) The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2015 Clinical Trials

108. Ability of a novel system for neonatal extracorporeal renal replacement therapy with an ultra-small volume circuit to remove solutes in vitro. (Abstract)

Ability of a novel system for neonatal extracorporeal renal replacement therapy with an ultra-small volume circuit to remove solutes in vitro. We automated our manual, syringe-driven extracorporeal renal replacement therapy (eRRT) system with an ultra-small volume circuit (3.2 ml) that is suitable for neonates without blood priming. Our objective was to determine the solute clearance and water balance of the automated and manual systems in vitro.Stored whole blood samples containing exogenous (...) urea, creatinine (Cr), potassium (K), and ammonia (NH3) to imitate acute kidney injury (AKI) and hyperammonemia were dialyzed for 3 h (blood flow, 4.0 ml/min; dialysate flow, 600 ml/h) with a continuous infusion of heparin. Solute clearance and sample weight were then compared with values before dialysis.The median clearance of blood urea nitrogen, Cr, K, and NH3 ranged from 1.7 to 2.3 and from 2.4 to 2.6 ml/min, and the median weight of the samples was decreased by 3.8 g and increased by 8.3 g

2015 Pediatric Nephrology

109. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomized controlled trial (AKIKI). Full Text available with Trip Pro

Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomized controlled trial (AKIKI). There is currently no validated strategy for the timing of renal replacement therapy (RRT) for acute kidney injury (AKI) in the intensive care unit (ICU) when short-term life-threatening metabolic abnormalities are absent. No adequately powered prospective randomized study has addressed this issue to date. As a result, significant practice (...) ' strategy, clinical and metabolic conditions are closely monitored and RRT is initiated only when one or more events (severity criteria) occur, including: oliguria or anuria for more than 72 hours after randomization, serum urea concentration >40 mmol/l, serum potassium concentration >6 mmol/l, serum potassium concentration >5.5 mmol/l persisting despite medical treatment, arterial blood pH <7.15 in a context of pure metabolic acidosis (PaCO2 < 35 mmHg) or in a context of mixed acidosis with a PaCO2

2015 Trials Controlled trial quality: predicted high

110. Hormone Replacement Therapy on the Postmenopausal Endometrium

receptors Additional relevant MeSH terms: Layout table for MeSH terms Hormones Tibolone Drospirenone Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Mineralocorticoid Receptor Antagonists Hormone Antagonists Diuretics, Potassium Sparing Diuretics Natriuretic Agents Androgen Antagonists Antihypertensive Agents Antineoplastic Agents, Hormonal Antineoplastic Agents Estrogen Receptor Modulators Anabolic Agents (...) Hormone Replacement Therapy on the Postmenopausal Endometrium Hormone Replacement Therapy on the Postmenopausal Endometrium - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Hormone Replacement Therapy

2015 Clinical Trials

111. Understanding the patterns and trends of sodium intake, potassium intake, and sodium to potassium ratio and their effect on hypertension in China. Full Text available with Trip Pro

in processed foods, the major public health strategy in Western countries, may be less effective in China, where salt intake remains high. Replacing sodium with potassium in salt to control and prevent hypertension in China should be considered along with other public health and clinical prevention options. (...) Understanding the patterns and trends of sodium intake, potassium intake, and sodium to potassium ratio and their effect on hypertension in China. Recent studies have shown inconsistent effects of sodium reduction, potassium intake, and the ratio of sodium to potassium (Na/K ratio) on hypertension and other cardiovascular diseases. Major gaps exist in knowledge regarding these issues in China.We analyzed the patterns and trends of dietary sodium intake, potassium intake, and the Na/K ratio

2014 American Journal of Clinical Nutrition

112. Treatment of Palpitations Due To Benign PVCs: Potassium, Magnesium and Lifestyle Adjustment

as time permits. Another way to supplement potassium is with “salt substitutes” like Nu-salt or Morton’s salt substitute. A brief look into this , however, tells me that it is a very complicated field. The best way to raise potassium levels is by eating foods with good potassium levels which I believe I listed in the post. Pingback: I have no idea if I am having PVCs or not. I’m currently out of the country traveling and these just started 2 week ago. I am a non-smoker, moderate drinker, walk 1 hour (...) Treatment of Palpitations Due To Benign PVCs: Potassium, Magnesium and Lifestyle Adjustment Treatment of Palpitations Due To Benign PVCs: Potassium, Magnesium and Lifestyle Adjustment | The Skeptical Cardiologist Primary Menu Search for: , , Treatment of Palpitations Due To Benign PVCs: Potassium, Magnesium and Lifestyle Adjustment In a , the skeptical cardiologist pontificated on the causes and evaluation of the most common cause of palpitations: premature ventricular contractions or PVCs

2017 The Skeptical Cardiologist

113. China Salt Substitute and Stroke Study

-fatal strokes a home visit will be made. A series of process indicators including urinary sodium, urinary potassium, blood pressure, knowledge about sodium and use of salt substitute will also be measured on a random sample of at least 20 individuals drawn from a random selection of 60 villages at baseline and every year thereafter. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 21000 participants Allocation: Randomized (...) to Arm Intervention/treatment No Intervention: Control Dietary advice at baseline only Experimental: Dietary sodium reduction Dietary advice and reduced-sodium added-potassium salt substitute Behavioral: Dietary sodium reduction Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute Other Name: Reduced-sodium added-potassium salt substitute Outcome Measures Go to Primary Outcome Measures : Stroke [ Time Frame: 5 years ] The primary outcome will be stroke defined

2014 Clinical Trials

114. Launching a salt substitute to reduce blood pressure at the population level: a cluster randomized stepped wedge trial in Peru. Full Text available with Trip Pro

of a population-level intervention based on sodium reduction and potassium increase - in practice, introducing a low-sodium, high-potassium salt substitute - on adult blood pressure levels.The proposed implementation research study includes two components: Phase 1, an exploratory component, and Phase 2, an intervention component. The exploratory component involves a triangle taste test and a formative research study designed to gain an understanding of the best implementation methods. Phase 2 involves (...) Launching a salt substitute to reduce blood pressure at the population level: a cluster randomized stepped wedge trial in Peru. Controlling hypertension rates and maintaining normal blood pressure, particularly in resource-constrained settings, represent ongoing challenges of effective and affordable implementation in health care. One of the strategies being largely advocated to improve high blood pressure calls for salt reduction strategies. This study aims to estimate the impact

2014 Trials Controlled trial quality: uncertain

115. Removing Potatoes from Children's Diets May Compromise Potassium Intake Full Text available with Trip Pro

Removing Potatoes from Children's Diets May Compromise Potassium Intake White potatoes are a forgotten source of nutrients. The goal of this study was to identify the nutritional implications of replacing a composite of white potatoes with a composite of vegetables commonly consumed by children aged 2-18 y (n = 3460) in a nationally representative sample. The NHANES 2005-2012 24-h dietary recall data were used to determine nutrient intake. Two replacement models were developed: one for potato (...) consumers and another for those consuming vegetables other than potatoes. Analyses focused on 1) mean nutrient contributions per 1 cup equivalent vegetable composite (VC)/potato composite (PC) consumed by participants, and 2) mean daily nutrient intake when the nutrients per 1 cup equivalent PC replaced the nutrients per 1 cup equivalent VC. Covariate adjusted analysis was tested for statistical significance (P < 0.002). When 1 cup equivalent VC replaced 1 cup equivalent PC, significantly lower mean

2016 Advances in Nutrition

116. AtKC1 and CIPK23 Synergistically Modulate AKT1-Mediated Low-Potassium Stress Responses in Arabidopsis Full Text available with Trip Pro

AtKC1 and CIPK23 Synergistically Modulate AKT1-Mediated Low-Potassium Stress Responses in Arabidopsis In Arabidopsis (Arabidopsis thaliana), the Shaker K(+) channel AKT1 conducts K(+) uptake in root cells, and its activity is regulated by CBL1/9-CIPK23 complexes as well as by the AtKC1 channel subunit. CIPK23 and AtKC1 are both involved in the AKT1-mediated low-K(+) (LK) response; however, the relationship between them remains unclear. In this study, we screened suppressors of low-K (...) (+) sensitive [lks1 (cipk23)] and isolated the suppressor of lks1 (sls1) mutant, which suppressed the leaf chlorosis phenotype of lks1 under LK conditions. Map-based cloning revealed a point mutation in AtKC1 of sls1 that led to an amino acid substitution (G322D) in the S6 region of AtKC1. The G322D substitution generated a gain-of-function mutation, AtKC1(D), that enhanced K(+) uptake capacity and LK tolerance in Arabidopsis. Structural prediction suggested that glycine-322 is highly conserved in K

2016 Plant physiology

117. Nicotine inhibits potassium currents in Aplysia bag cell neurons Full Text available with Trip Pro

Nicotine inhibits potassium currents in Aplysia bag cell neurons Acetylcholine and the archetypal cholinergic agonist, nicotine, are typically associated with the opening of ionotropic receptors. In the bag cell neurons, which govern the reproductive behavior of the marine snail, Aplysia californica, there are two cholinergic responses: a relatively large acetylcholine-induced current and a relatively small nicotine-induced current. Both currents are readily apparent at resting membrane (...) with the G protein blocker GDPβS or exposure to classical nicotinic antagonists but was occluded by replacing intracellular K(+) with Cs(+) Consistent with an underlying mechanism of direct inhibition of one or more K(+) channels, nicotine was found to rapidly reduce the fast-inactivating A-type K(+) current as well as both components of the delayed-rectifier K(+) current. Finally, nicotine increased bag cell neuron excitability, which manifested as reduction in spike threshold, greater action potential

2016 Journal of neurophysiology

118. The Magnetorheological Finishing (MRF) of Potassium Dihydrogen Phosphate (KDP) Crystal with Fe3O4 Nanoparticles Full Text available with Trip Pro

The Magnetorheological Finishing (MRF) of Potassium Dihydrogen Phosphate (KDP) Crystal with Fe3O4 Nanoparticles The cubic Fe3O4 nanoparticles with sharp horns that display the size distribution between 100 and 200 nm are utilized to substitute the magnetic sensitive medium (carbonyl iron powders, CIPs) and abrasives (CeO2/diamond) simultaneously which are widely employed in conventional magnetorheological finishing fluid. The removal rate of this novel fluid is extremely low compared (...) in the fringe of spot are loose. The surface texture as well as figure accuracy and PSD1 (power spectrum density) of potassium dihydrogen phosphate (KDP) is greatly improved after MRF, which clearly prove the feasibility of substituting CIP and abrasive with Fe3O4 in our novel MRF design.

2016 Nanoscale research letters

119. Dietary Impact of Adding Potassium Chloride to Foods as a Sodium Reduction Technique Full Text available with Trip Pro

, to enable a maximum daily sodium chloride intake of 5 grams/day, were applied to all foods consumed in the survey. The impact of replacing 20%, 50% and 100% of sodium chloride from each product with potassium chloride was modeled. At baseline median, potassium intake was 3334 mg/day. An increase in the median intake of potassium of 453 mg/day was seen when a 20% replacement was applied, 674 mg/day with a 50% replacement scenario and 733 mg/day with a 100% replacement scenario. Reformulation had (...) the largest impact on: bread, processed fruit and vegetables, snacks and processed meat. Replacement of sodium chloride by potassium chloride, particularly in key contributing product groups, would result in better compliance to potassium intake guidelines (3510 mg/day). Moreover, it could be considered safe for the general adult population, as intake remains compliant with EFSA guidelines. Based on current modeling potassium chloride presents as a valuable, safe replacer for sodium chloride in food

2016 Nutrients

120. Calmodulin Regulates Human Ether à Go-Go 1 (hEAG1) Potassium Channels through Interactions of the Eag Domain with the Cyclic Nucleotide Binding Homology Domain Full Text available with Trip Pro

Calmodulin Regulates Human Ether à Go-Go 1 (hEAG1) Potassium Channels through Interactions of the Eag Domain with the Cyclic Nucleotide Binding Homology Domain The ether à go-go family of voltage-gated potassium channels is structurally distinct. The N terminus contains an eag domain (eagD) that contains a Per-Arnt-Sim (PAS) domain that is preceded by a conserved sequence of 25-27 amino acids known as the PAS-cap. The C terminus contains a region with homology to cyclic nucleotide binding (...) amplitudes partially recovered, but activation gating was slowed and shifted to depolarized potentials. Deletion of either the eagD or cNBHD abolished the inhibition by Ca(2+) i However, deletion of just the PAS-cap resulted in a >15-fold potentiation in response to elevated Ca(2+) i Mutations of residues at the interface between the eagD and cNBHD have been linked to human cancer. Glu-600 on the cNBHD, when substituted with residues with a larger volume, resulted in hEAG1 currents that were profoundly

2016 The Journal of biological chemistry

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>